



For immediate distribution

RULING IN FAVOUR OF BIORTHEX INC.

P
R
E
S
S

R
E
L
E
A
S
E

Montreal, CANADA, October 26, 2001 – In regards to the dispute involving Eric Weynant, Imago SA and Imago Technologies International inc. and Biorthex inc. relating to the exclusive rights to use a porous Titanium-Nickel Alloy technology, Biorthex inc. announced today that a ruling was rendered in its favour on October 1st.

Justice Dominique Gueguen, Vice-Président, juge délégué par le Président du Tribunal de Grande Instance de Paris, concluded that the claims of Eric Weynant and Imago Technologies International inc. were unfounded and therefore ordered the withdrawal of the two court orders rendered on November 6th, 2000 and January 22nd, 2001 relating to the delivery of copies of contracts in the possession of Biorthex inc.

In addition, Imago Technologies International inc. and Mr. Weynant were jointly sentenced to pay a lump sum to Biorthex inc.

Biorthex inc. uses an innovative technology, Actipore™, in accordance with exclusive rights granted by it's partners pursuant to the terms of which the company, among others, has been granted a licence and property rights on the patents for the use of the said technology throughout the world, except in Russia.

"The ruling rendered by Justice Gueguen is very positive and demonstrates our means of defence for dealing with unfounded accusations", says President and CEO of Biorthex inc., Sylvain Gareau.

Biorthex inc. is a biotechnology company that designs, develops and markets innovative products for the surgical treatment of spinal disorders to become a leader in the field of orthopaedics.

- 30 -

For information:

Sylvain Gareau
President and CEO
Biorthex Inc.
(514) 382-4800, ext. 206

Renelle Lacasse
Communications Advisor
Biorthex inc.
(514) 382-4800, ext. 224

01-10-26 14:40

Biorthex Inc.

9001 l'Acadie Blvd., Suite 802, Montreal, Quebec H4N 3H5 CANADA